Pamidronate therapy in an adolescent patient chronic diffuse sclerosing osteomyelitis: Report of a case

Chronic diffuse sclerosing osteomyelitis is a rare, non-suppurative mandibular inflammatory disease with recurrent pain and swelling and no standardized treatment guidelines. This report described a 13-year-old girl with left mandibular chronic diffuse sclerosing osteomyelitis who achieved clinical and radiologic remission after a three-day intravenous pamidronate regimen (0.5 mg/kg on day 1 and 1.0 mg/kg on days 2–3, up to 30 mg/day) and favorable bone remodeling on follow-up imaging. These findings indicate that pamidronate may be an effective and safe therapeutic option for pediatric chronic diffuse sclerosing osteomyelitis, with bone turnover markers serving as useful adjunct indicators of treatment response.

Authors

Institutions

Publication Details

Journal
The Journal of The Korean Dental Association
Published
2026-06-30
DOI
https://doi.org/10.22974/jkda.2026.64.6.002
Primary Topic
Osteomyelitis and Bone Disorders Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Pamidronate therapy in an adolescent patient chronic diffuse sclerosing osteomyelitis: Report of a case

Woo‐Jin Jeon, Kil-Hwa Yoo, Chul-Min Park, Chan-Sik Yoon
The Journal of The Korean Dental Association
Osteomyelitis and Bone Disorders Research
article

Pamidronate therapy in an adolescent patient chronic diffuse sclerosing osteomyelitis: Report of a case

Woo‐Jin Jeon, Kil-Hwa Yoo, Chul-Min Park, Chan-Sik Yoon
article en

Abstract

Chronic diffuse sclerosing osteomyelitis is a rare, non-suppurative mandibular inflammatory disease with recurrent pain and swelling and no standardized treatment guidelines. This report described a 13-year-old girl with left mandibular chronic diffuse sclerosing osteomyelitis who achieved clinical and radiologic remission after a three-day intravenous pamidronate regimen (0.5 mg/kg on day 1 and 1.0 mg/kg on days 2–3, up to 30 mg/day) and favorable bone remodeling on follow-up imaging. These findings indicate that pamidronate may be an effective and safe therapeutic option for pediatric chronic diffuse sclerosing osteomyelitis, with bone turnover markers serving as useful adjunct indicators of treatment response.

The Journal of The Korean Dental AssociationVol. 64(6)
Daejeon Sun Hospital (KR)
Good health and well-being
Openalex Percentile: Top 8%
Osteomyelitis and Bone Disorders Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.